Forty-One Recent Cases of Invasive Zygomycosis From a Global Clinical Registry.

Rueping, M.; Heinz, Werner; Kindo, Anupma Jyoti; Rickerts, Volker; Lass-Floerl, Cornelia; Beisel, Claudia; Herbrecht, Raoul; Roth, Yehudah; Silling, Gerda; Ullmann, Andrew J.; Borchert, K; Egerer, Gerlinda; Maertens, J; Maschmeyer, Georg; Simon, Arne; Wattad, Morad; Fischer, Gustave-Nicolas; Vehreschild, J. J.; Karthaus, Meinolf; Cornely, Oliver A.

doi:10.1182/blood.v114.22.4736.4736

Cited by 21 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mucormycosis is an infection affecting all ages, from premature neonates to elderly people with varying types of underlying conditions [5,[11][12][13]. While the incidence rates of invasive mucormycosis in these diverse patient groups have not been well studied, the current data demonstrate increased incidence in a wide range of specific immunocompromised patient groups [2,5,11].…”

Section: Patient Population At Risk For Mucormycosismentioning

confidence: 73%

“…In the most contemporary epidemiologic study of mucormycosis in Europe, the most common underlying diseases were haematological malignancies (44%) followed by diabetes mellitus (17%) and trauma (17%) [2]. Data from a global fungal infection registry that included patients from central Europe and Asia demonstrated that malignancy (63%), diabetes (17%) and solid organ transplantation (10%) predominated as underlying conditions for mucormycosis [11].…”

Section: Patient Population At Risk For Mucormycosismentioning

confidence: 99%

See 1 more Smart Citation

Why is mucormycosis more difficult to cure than more common mycoses?

Katragkou

Walsh

Roilides

2014

Clinical Microbiology and Infection

132

135

View full text Add to dashboard Cite

Although considered to be a rare infection, mucormycosis (zygomycosis) has emerged as the second most common invasive mould infection. Despite the advent of newer antifungal agents, mortality rate of mucormycosis remains exceedingly high. Successful management of mucormycosis requires early diagnosis, reversal of underlying predisposing risk factors, surgical debridement and prompt administration of active antifungal agents. However, mucormycosis is not always amenable to cure. There are challenging obstacles that lead to difficulties in management of amphotericin B. These include unique host-based risk factors for mucormycosis, the fungus' resistance to innate host defences and distinctive features of its immunopathogenesis, such as extensive angioinvasion, increased virulence and use of chelators by the fungus as siderophores. In addition to these obstacles, the difficulties in early diagnosis, including nonspecific clinical manifestations, lack of serological methods, as well limitations of culture and molecular methods, lead to delay in initiation of antifungal therapy. Finally, the variability of susceptibility to amphotericin B and resistance to most other conventional antifungal agents leads to major limitations in successful treatment of this devastating infection.

show abstract

Section: Patient Population At Risk For Mucormycosismentioning

confidence: 73%

Section: Patient Population At Risk For Mucormycosismentioning

confidence: 99%

Why is mucormycosis more difficult to cure than more common mycoses?

Katragkou

Walsh

Roilides

2014

Clinical Microbiology and Infection

132

135

View full text Add to dashboard Cite

show abstract

“…Registration of cases, despite the difficulties in implementation, is the only method to collect information about rare diseases, such as mucormycosis. Initiatives, such as the Fungiscope â , a Global Registry for Emerging Fungal Infections, have contributed significantly to the current knowledge of rare fungal infections including mucormycosis; in an article of 2010 [19], data from 41 zygomycosis cases from Europe and Asia were analysed. In Europe, the largest registry for mucormycosis is the one constructed by the previously ECMM and currently ECMM/ISHAM Working Group on Zygomycosis (www.zygomyco.net).…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of mucormycosis in Europe

Petrikkos

Skiada

Drogari‐Apiranthitou

2014

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Zygomycosis (mucormycosis) is being increasingly recognized as causing infection in recent years. National and multinational European surveys attempting to analyse the epidemiological parameters of this potentially devastating infection are very few. Although the exact incidence could not be defined due to the different methodologies used in these studies and the absence of a denominator, there were some useful observations made regarding the clinical presentation, sites of infection and diagnostic practices. Moreover, the importance for a prompt and accurate diagnosis has been stressed. As early diagnosis can significantly affect the initiation of treatment and decrease mortality, future research should focus on the development of an epidemiological risk assessment tool and novel diagnostic methods.

show abstract

“…Even with early diagnosis and appropriate surgical and medical therapy, the mortality rate is high. [1][2][3][4][5][6] For this reason, a high degree of suspicion is needed, to initiate treatment promptly.…”

Section: Introductionmentioning

confidence: 99%

Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases

Däbritz

Attarbaschi

Tintelnot

et al. 2011

Mycoses

View full text Add to dashboard Cite

Mucormycosis is associated with high morbidity and mortality and is perceived as an emerging fungal infection. However, contemporary paediatric data are limited. We present a series of paediatric cases of mucormycosis reported from Germany and Austria collected within a voluntary epidemiological survey through standardised, anonymized case report forms. Twelve cases were reported between January 2004 and December 2008 (six men; mean age: 12.6 years, range: 0.1-17 years). Mucormycosis was proven in nine, and probable in three cases. Isolates included Lichtheimia (syn. Absidia pro parte, Mycocladus) (five), Rhizopus (three) and Mucor (one) species. Infection was limited to soft tissue in three cases, the lung in two cases, and an infected thrombus in one case; rhinocerebral disease was found in three cases, and pulmonary-mediastinal, pulmonary-cerebral and soft tissue-cerebral involvement in one case each. All three patients with isolated soft tissue infection were cured, whereas seven of the remaining patients died (one patient without follow-up). The overall mortality rate was 67%. While these data cannot provide conclusive data on incidence and disease burden of mucormycosis in paediatric patients, they reflect the continuing threat of these infections to immunocompromised patients and the need for improved diagnosis and management.

show abstract

Forty-One Recent Cases of Invasive Zygomycosis From a Global Clinical Registry.

Cited by 21 publications

References 0 publications

Why is mucormycosis more difficult to cure than more common mycoses?

Why is mucormycosis more difficult to cure than more common mycoses?

Epidemiology of mucormycosis in Europe

Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases

Contact Info

Product

Resources

About